Does candesartan benefit patients with heart failure?
Christian Torp-Pedersen* and Lars Køber
Correspondence *Department of Cardiology, Bispebjerg Hospital, University of Copenhagen, 2400 København NV, Copenhagen, Denmark
Email ctp@heart.dk
This article has no abstract so we have provided the first paragraph of the full text.
Can an ARB prevent cardiovascular death and myocardial infarction in patients with heart failure? Furthermore, should ARB therapy even be added to ACE inhibitor therapy? These are the clinical questions addressed by Demers et al. in this exploration of the CHARM trial findings.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
